@article{3c154e5515f44654816ae6fb518fc770,
title = "Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics",
abstract = "More oncology biologics are becoming available for subcutaneous (sc.) administration and are expected to provide useful therapeutic options. We evaluated evidence published in the past 5 years to assess the humanistic and economic impact of sc. versus intravenous administration of approved cancer therapies and identify outcomes favoring either administration route. These publications focused predominantly on healthcare resource utilization and economic outcomes, demonstrating resource and cost savings with sc. administration. Patients reported a better health-related quality of life and preference for sc. formulations. Time-and-motion study analyses confirmed the convenience of sc. administration. These findings suggest that future availability of sc. oncology biologics, especially anti-PD-1/PD-ligand 1 antibodies due to their increased utility in various malignancies, may be beneficial for patients, healthcare providers and payers.",
keywords = "biologic, cancer, cost, HCRU, HRQoL, intravenous, preference, subcutaneous, tolerability",
author = "Anderson, {Kenneth C.} and Ola Landgren and Arend, {Rebecca C.} and Jeffrey Chou and Jacobs, {Ira A.}",
note = "Funding Information: KC Anderson is consultant for Bristol-Myers Squibb, Celgene, Gilead, Janssen and Millennium-Takeda. O Landgren has disclosed grant support from the National Institutes of Health (NIH), Food and Drug Administration (FDA), Leukemia and Lymphoma Society (LLS), Multiple Myeloma Research Foundation (MMRF), IMF, Perelman Family Foundation, Rising Tides Foundation, Amgen, Cel-gene, Glenmark, Janssen, Karyopharm, Seattle Genetics and Takeda; advisory boards/honoraria from Adaptive, Amgen, Binding Site, Bristol-Myers Squibb, Celgene, Cellectis, Glenmark, Janssen, Juno and Pfizer; and participation in Independent Data Monitoring Committees for Janssen, Merck and Takeda. RC Arend has disclosed advisory board honoraria from AstraZeneca, Clovis, Pfizer and Tesaro. J Chou and IA Jacobs are employees of Pfizer and hold stock/stock options in Pfizer. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Medical writing was provided by S Mariani, of Engage Scientific Solutions and was funded by Pfizer. Publisher Copyright: {\textcopyright} 2019 {\textcopyright} 2019 Pfizer Inc.",
year = "2019",
doi = "10.2217/fon-2019-0368",
language = "English (US)",
volume = "15",
pages = "3267--3281",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "28",
}
